Windlas Biotech (NSE:WINDLAS) Construction In Progress: ₹562 Mil (As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
86 GF Score
Price ₹859.00
GF Value ₹936.98
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Construction In Progress?

Windlas Biotech NSE:WINDLAS -0.56% 86 Construction In Progress is ₹562 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 86/100 and a GF Value™ of ₹936.98 (Fairly Valued). The stock has 1 warning sign investors should review.

Windlas Biotech's quarterly construction in progress declined from Sep. 2025 (₹242 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹562 Mil).

Windlas Biotech's annual construction in progress declined from Mar. 2024 (₹105 Mil) to Mar. 2025 (₹48 Mil) but then increased from Mar. 2025 (₹48 Mil) to Mar. 2026 (₹562 Mil).

Windlas Biotech Construction In Progress Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Construction In Progress Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial 77.34 525.72 105.40 48.33 561.55

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.33 0.00 242.42 0.00 561.55
NSE:WINDLAS
86GF Score
Windlas Biotech Ltd NSE:WINDLAS
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹562 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Construction In Progress of ₹562 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Construction In Progress too high?
Windlas Biotech's current Construction In Progress is ₹562 Mil. Overall, Windlas Biotech has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Construction In Progress compare to ZTS?
Windlas Biotech's Construction In Progress of ₹562 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Construction In Progress is ₹562 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.98, compared to a current price of ₹859.00 — trading 8.3% below its estimated fair value. The current Construction In Progress is ₹562 Mil. Windlas Biotech's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Construction In Progress is ₹562 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹859.00 is trading 8.3% below its estimated GF Value™ of ₹936.98. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • Construction In Progress: ₹562 Mil
  • GF Value™: ₹936.98 vs. price of ₹859.00 (8.3% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
86GF Score

Get the complete analysis for NSE:WINDLAS

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹859.00
Price
₹936.98
GF Value